Furthermore, BCL-xL inhibition significantly reduced the tumor burden in a mouse xenograft model, suggesting that targeting BCL-xL could offer a promising therapeutic strategy for erythroid/megakaryoblastic leukemias and highlighting a subgroup of AML with reduced sensitivity to VEN-based treatments [77]. Here, BCL2L1 is linked to acute myeloid leukemia.